Connor, Clark & Lunn Investment Management Ltd.

Position in ZNTL — Zentalis Pharmaceuticals, Inc.

CIK 1596800 VANCOUVER, A1

Position in ZNTL

as of Mar 31, 2026 · filed May 11, 2026 Compact

Position Value

$1,853,282

+$790,758 QoQ

Shares Held

792,001

+0.6% QoQ

Ownership

1.11%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Mar 2024

9 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Mar 31, 2026

Connor, Clark & Lunn Investment Management Ltd. holds $703,286,486 across 100 Biotechnology names. ZNTL ranks #59 (0.3% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	VRTX	Vertex Pharmaceuticals Inc / Ma	251,711	$112,399,029
2	IONS	Ionis Pharmaceuticals Inc	874,089	$65,635,343
3	ARWR	Arrowhead Pharmaceuticals, Inc.	836,981	$52,478,708
4	MIRM	Mirum Pharmaceuticals, Inc.	479,476	$44,293,992
5	REGN	Regeneron Pharmaceuticals, Inc.	32,164	$24,851,192
6	AXSM	Axsome Therapeutics, Inc.	134,792	$22,782,543
7	SRPT	Sarepta Therapeutics, Inc.	1,019,951	$22,194,133
8	TERN	Terns Pharmaceuticals, Inc.	384,681	$20,280,382

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$1,853,282	792,001	+0.6%	Shares	Sole	2026-05-11
2025-12-31	$1,062,524	787,055	+106.7%	Shares	Sole	2026-02-10
2025-09-30	$575,041	380,822	+21.0%	Shares	Sole	2025-11-13
2025-06-30	$365,220	314,845	-12.8%	Shares	Sole	2025-08-07
2025-03-31	$574,365	361,236	+4.7%	Shares	Sole	2025-05-12
2024-12-31	$1,045,468	345,039	+50.6%	Shares	Sole	2025-02-10
2024-09-30	$843,227	229,138	+126.3%	Shares	Sole	2024-11-08
2024-06-30	$414,194	101,270	+420.1%	Shares	Sole	2024-08-09
2024-03-31	$306,862	19,471	—	Shares	Sole	2024-05-09
No filing history on record for this holder in this stock.